Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Monica Drera"'
Autor:
Anna Maria Pelizzari, Monica Drera, Mariella D’Adda, Marco Ungari, Daniela Marocolo, Fabio Facchetti, Daniela Bellotti, Sergio Barlati, Giuseppe Rossi
Publikováno v:
Haematologica, Vol 92, Iss 1 (2007)
Twenty-five elderly patients with oligoblastic acute myeloid leukemia (AML) received subcutaneous granulocyte colony-stimulating factor (filgrastim) in addition to supportive care. Ninety-two percent of the patients had multilineage dysplasia, 17% hy
Externí odkaz:
https://doaj.org/article/9e113159a8a54c4c883037db9927fc4a
Publikováno v:
Leukemia & Lymphoma. 49:2216-2218
Hydroxyurea (HU) is largely used for the treatment of chronic myeloproliferative disorders (CMPD). It is the first-choice therapy in patients with essential thrombocythemia aged > 60, where it can ...
Autor:
Fabio Facchetti, Samantha Ferrari, Giuseppe Rossi, Marco Ungari, Giovanni Cancarini, Regina Tardanico, Claudia Crippa, Monica Drera
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(9)
Autor:
Chiara Bottelli, Erika Borlenghi, Samantha Ferrari, Giuseppe Rossi, Monica Drera, Alessandra Tucci
Publikováno v:
Cancer. 115(19)
BACKGROUND: The authors set out to analyze if a simple comprehensive geriatric assessment (CGA) could objectively identify elderly patients with diffuse large cell lymphoma (DLCL) who can be effectively treated with anthracycline-containing immunoche
Autor:
Fabio Facchetti, Marco Ungari, Giuseppe Rossi, Daniela Bellotti, D. Marocolo, Monica Drera, Sergio Barlati, Mariella D'Adda, Anna Maria Pelizzari
Twenty-five elderly patients with oligoblastic acute myeloid leukemia (AML) received subcutaneous granulocyte colony-stimulating factor (filgrastim) in addition to supportive care. Ninety-two percent of the patients had multilineage dysplasia, 17% hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31634026f5498554398f2a49c048ce8
http://hdl.handle.net/11379/28271
http://hdl.handle.net/11379/28271
Autor:
Daniele Laszlo, Giovanna Andreola, Aleksandra Babic, Giovanni Martinelli, Monica Drera, Cristina Rabascio, Elezi Rufije, Ambra Malerba, Mara Negri
Publikováno v:
Blood. 118:2994-2994
Abstract 2994 Patients affected by hematologic malignancies might benefit from high dose chemotherapy followed by peripheral stem cells (PBSC) transplant. Chemotherapy in combination with G-CSF is effective in mobilizing stem cells but often toxic, m
Autor:
Elisa Cerqui, Giuseppe Rossi, Marco Chiarini, Luigi Caimi, Monica Drera, Claudia Ghidini, Luisa Imberti, Cinzia Zanotti, Marina Motta
Publikováno v:
Blood. 114:2353-2353
Abstract 2353 Poster Board II-330 Background Chronic lymphocytic leukemia (CLL) results in accumulation of mature, malignant, monoclonal B cells in blood, lymph nodes, spleen, liver, and bone marrow. Patients with CLL have fundamental defects in both
Autor:
Monica Drera, Samantha Ferrari, Claudia Crippa, Giuseppe Rossi, Antonio Regazzoli, Marinella Calarco
Publikováno v:
Blood. 114:2892-2892
Abstract 2892 Poster Board II-868 Background and aim. While multiple myeloma (MM) still remains largely incurable, therapeutic options for patients with MM are expanding. However the best way to use the different effective regimens, either in combina
Autor:
Massimiliano De Vecchi, Giampiero Carosi, Chiara Cattaneo, Monica Drera, Erika Borlenghi, Alessandro Re, Maria Adele Capucci, Liana Signorini, Anna Maria Pelizzari, Francesca Bracchi, Giuseppe Rossi, Salvatore Casari
Publikováno v:
Blood. 112:4835-4835
Background. Bloodstream infections (BSI) represent a frequent and potentially life-threatening complication among hematological patients (pts). Aims, Patients and Methods. To evaluate the recent epidemiology, emerging resistant strains, risk factors
Autor:
Samantha Ferrari, Giuseppe Rossi, Erika Borlenghi, Chiara Bottelli, Monica Drera, Alessandra Tucci
Publikováno v:
Blood. 110:3441-3441
Introduction: Defining the optimal treatment strategy for elderly patients (pts) with diffuse large cell lymphoma (DLCL) represents a major challenge, since age, end-organ damage and comorbidities often preclude the delivery of full-dose intensive th